Dr. Lorenz Raber recaps the PACMAN-AMI study and how the PCSK9 inhibitor alirocumab can aid in coronary plaque regression.
Dr. Lorenz Raber recaps the PACMAN-AMI study and how the PCSK9 inhibitor alirocumab can aid in coronary plaque regression.